Hyperprolactinemia.

Prolactinomas are the most common pituitary tumors. Hyperprolactinemia is characterized by increased production of prolactin, often leading to reproductive dysfunction and galactorrhea. Prolactinomas may also cause male-factor infertility by producing hypogonadism. In addition, if large, they can produce neurologic symptoms by mass effect in the sellar area. The diagnostic evaluation first requires exclusion of other causes of hyperprolactinemia, such as pregnancy, primary hypothyroidism, numerous medications, and miscellaneous causes. The second step in the diagnostic evaluation is to perform a head scan, preferably an MRI. This is essential in order to exclude a "pseudoprolactinoma" which would require surgery. Following diagnostic evaluation, the next step is to determine whether a patient with hyperprolactinemia has an indication for therapy, such as a macroprolactinoma (tumor >1 cm), hypogonadism (risk of osteoporosis), infertility, significant galactorrhea, acne, hirsutism, or headache. The treatment of choice for nearly all patients with hyperprolactinemic disorders is medical. In most cases, dopamine agonists (bromocriptine, pergolide, cabergoline) are extremely effective in lowering serum prolactin, restoring gonadal function, decreasing tumor size, and improving visual fields. The main limitation is side effects, particularly nausea or orthostatic dizziness. The newest dopamine agonist, cabergoline, can be given just once or twice a week, is more effective in normalizing prolactin and restoring menses than bromocriptine, and is significantly better tolerated. However, it is not yet recommended as first-line therapy for patients seeking fertility, because adequate safety data in pregnancy are not available. For the infrequent patient unable to tolerate, or resistant to, medical therapy, neurosurgical transsphenoidal resection may be necessary, particularly if the patient has a large lesion jeopardizing the optic chiasm. Hyperprolactinemia is a rewarding disorder to manage because patients typically respond well to medication, with restoration of menses and fertility.

[1]  W. Blackard,et al.  Persistent defect in regulation of prolactin secretion after successful pituitary tumor removal in women with the galactorrhea-amenorrhea syndrome. , 1980, The Journal of clinical endocrinology and metabolism.

[2]  J. Stangel,et al.  Incidence of Hyperprolactinemia During Oral Contraceptive Therapy , 1980, Obstetrics and gynecology.

[3]  G. Teasdale,et al.  TESTS OF PROLACTIN SECRETION IN DIAGNOSIS OF PROLACTINOMAS , 1979, The Lancet.

[4]  A. Frantz,et al.  Large molecular size prolactin with reduced receptor activity in human serum: high proportion in basal state and reduction after thyrotropin-releasing hormone. , 1979, The Journal of clinical endocrinology and metabolism.

[5]  S. Sherlock,et al.  Serum prolactin in liver disease and its relationship to gynaecomastia. , 1978, Gut.

[6]  J. Maroon,et al.  Chlorpromazine-induced changes in serum prolactin in women with oligomenorrhea, amenorrhea, and pituitary adenoma. , 1977, Fertility and sterility.

[7]  G. L. Noel,et al.  Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. , 1977, The New England journal of medicine.

[8]  M. L'hermite,et al.  Serum prolactin levels during the menstrual cycle. , 1977, The Journal of clinical endocrinology and metabolism.

[9]  C. Faiman,et al.  Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. , 1977, The American journal of medicine.

[10]  P. A. Lee,et al.  Puberty in girls: correlation of serum levels of gonadotropins, prolactin, androgens, estrogens, and progestins with physical changes. , 1976, The Journal of clinical endocrinology and metabolism.

[11]  J. Bonnar,et al.  Effect of breast-feeding on pituitary-ovarian function after childbirth , 1975, British medical journal.

[12]  A. Frantz,et al.  Size heterogeneity of human prolactin in plasma and pituitary extracts. , 1974, The Journal of clinical endocrinology and metabolism.

[13]  D. Parker,et al.  Relation of sleep-entrained human prolactin release to REM-nonREM cycles. , 1974, The Journal of clinical endocrinology and metabolism.

[14]  T. Chard,et al.  CIRCULATING LEVELS OF PROLACTIN DURING THE MENSTRUAL CYCLE , 1974, Clinical endocrinology.

[15]  A. Frantz,et al.  The nocturnal rise of human prolactin is dependent on sleep. , 1973, The Journal of clinical endocrinology and metabolism.

[16]  A. Frantz,et al.  Human Prolactin: 24-Hour Pattern with Increased Release doring Sleep , 1972, Science.

[17]  F. Naftolin,et al.  Breast examination does not elevate serum prolactin. , 1980, Fertility and sterility.

[18]  L. Frohman,et al.  Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. , 1979, The Journal of clinical endocrinology and metabolism.

[19]  K. Kellett,et al.  Serum prolactin levels in untreated primary hypothyroidism. , 1978, The American journal of medicine.

[20]  J. Winter,et al.  Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels. , 1977, American journal of obstetrics and gynecology.

[21]  H. Friesen,et al.  Factors influencing the secretion of human prolactin and growth hormone in menstrual and gestational women. , 1973, American journal of obstetrics and gynecology.